All In Biotech

NDA 022563 · Mayne Pharma

Sorilux

Calcipotriene · Topical · Vitamin D Analog

Last checked: Nov 19, 2026Latest source record: Nov 5, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Oct 6, 2010

Approved uses

4

Original approval plus efficacy supplements

Registered trials

167

41 Phase 3, 8 recruiting

FAERS reports

3,507

1,417 serious, 69 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 9, 2024.

Calcipotriene foam is indicated for the topical treatment of plaque psoriasis of the scalp and body in adults and pediatric patients 4 years of age and older. Calcipotriene foam, is a vitamin D analog indicated for the topical treatment of plaque psoriasis of the scalp and body in adults and pediatric patients 4 years of age and older. ( 1 )

Mechanism: Calcipotriene is a synthetic vitamin D3 analog that has a similar receptor binding affinity as natural vitamin D3. However, the exact mechanism of action contributing to the clinical efficacy in the treatment of psoriasis is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • SORILUX · CALCIPOTRIENE 0.005% · AEROSOL, FOAM, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Calcipotriene" as an intervention, any sponsor and status, largest first.

All 167 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective843
  • psoriasis736
  • diarrhoea216
  • arthralgia205
  • rash197
  • nausea190
  • pain189
  • pruritus184
  • off label use179
  • headache174
  • product use in unapproved indication159
  • fatigue150

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20046
200510
200612
200716
200831
200921
201024
20116
201229
201353
201455
2015136
2016149
2017173
2018185
2019247
2020230
2021230
2022223
2023947
2024256
2025265
2026203

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Sorilux (Calcipotriene)

2024 spending

$265K

Beneficiaries

80

158 claims

Per beneficiary

$3,314

$13.94 per unit

View as table
YearSpending
2020$855,174
2021$646,478
2022$416,095
2023$350,869
2024$265,110

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 81 on PubMed

Sponsor: Mayne Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.